top of page
-Photoroom.png)
מן העיתונות
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in...
NEXALIN
13 במאיזמן קריאה 5 דקות
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
HOUSTON, May 06, 2025 — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial...
NEXALIN
6 במאיזמן קריאה 3 דקות
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock
HOUSTON, May 05, 2025 — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial...
NEXALIN
5 במאיזמן קריאה 3 דקות
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
Company initiates formal regulatory engagement on trial design for Alzheimer’s, dementia, and MCI indications HOUSTON, TX, May 01, 2025 —...
NEXALIN
1 במאיזמן קריאה 3 דקות
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
HOUSTON, TX, April 24, 2025 — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial...
NEXALIN
24 באפר׳זמן קריאה 3 דקות
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™ HOUSTON, TX, April...
NEXALIN
23 באפר׳זמן קריאה 4 דקות
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
Proposed bipartisan legislation would expand Medicare reimbursement pathways for AI-enabled medical devices – a framework that supports...
NEXALIN
21 באפר׳זמן קריאה 4 דקות
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
Patent Approval Reinforces Nexalin’s Leadership in Non-Invasive Brain Stimulation for Addiction Treatment HOUSTON, TX, April 14, 2025 —...
NEXALIN
14 באפר׳זמן קריאה 4 דקות
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in...
NEXALIN
2 באפר׳זמן קריאה 3 דקות
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) is pleased to...
NEXALIN
26 במרץזמן קריאה 2 דקות
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use...
NEXALIN
3 במרץזמן קריאה 3 דקות
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials HOUSTON, TX, Feb. 28, 2025 (GLOBE NEWSWIRE) — Nexalin...
NEXALIN
28 בפבר׳זמן קריאה 3 דקות
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
HOUSTON, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in...
NEXALIN
26 בפבר׳זמן קריאה 3 דקות
NEXALIN
19 בפבר׳זמן קריאה 0 דקות
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
HOUSTON, TEXAS, Feb. 10, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in...
NEXALIN
10 בפבר׳זמן קריאה 2 דקות
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in...
NEXALIN
3 בפבר׳זמן קריאה 4 דקות
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
HOUSTON, TX, Jan. 23, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to...
NEXALIN
23 בינו׳זמן קריאה 2 דקות
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
DIFS Technology: A Potential Game-Changer for Mental Health Treatments Setting New Benchmarks: 65% Response Rate Shown in Completed...
NEXALIN
14 בינו׳זמן קריאה 5 דקות
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
AI Components for Electronic Data Capture and Patient Monitoring to be Integrated into Phase 2 HOUSTON, TX, Dec. 23, 2024 (GLOBE...
NEXALIN
23 בדצמ׳ 2024זמן קריאה 4 דקות
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
Report Highlights Nexalin’s Unique Non-Invasive Solution Addressing Deep Brain Dysfunction, Positioned to Revolutionize Mental Health...
NEXALIN
26 בנוב׳ 2024זמן קריאה 3 דקות
bottom of page